TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BB Biotech ( (CH:BION) ) has provided an announcement.
BB Biotech AG has released its interim report for the first nine months of 2025, revealing a significant profit increase to CHF 106 million, compared to CHF 16 million in the same period last year. The third quarter alone saw a profit of CHF 448 million, a notable turnaround from a loss of CHF 157 million in the previous year, reflecting positive share price developments in its portfolio companies.
The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.
More about BB Biotech
BB Biotech AG is an investment company based in Schaffhausen, Switzerland, and is listed on the Swiss and German stock exchanges. Since 1993, it has focused on investing in innovative drug development companies, primarily located in the USA and Western Europe. The company is recognized as a leading investor in this sector, with its investment strategy and decisions guided by a skilled board of directors and an experienced investment management team from Bellevue Asset Management AG.
Average Trading Volume: 94,300
Technical Sentiment Signal: Hold
Current Market Cap: CHF2.14B
Learn more about BION stock on TipRanks’ Stock Analysis page.